SELLAS Life Sciences (SLS) Long-Term Deferred Tax (2011 - 2016)
SELLAS Life Sciences (SLS) posted quarterly Long-Term Deferred Tax of -$5.7 million for Q4 2016, down 4.49% year-over-year from -$5.9 million in Q1 2016, and down 4.49% quarter-over-quarter from -$5.4 million in Q4 2015.
SELLAS Life Sciences (SLS) Long-Term Deferred Tax (2011 - 2016) Analysis & Trends
SELLAS Life Sciences (SLS) has reported Long-Term Deferred Tax for 6 consecutive years, with -$5.7 million the latest figure, recorded in Q4 2016.
- In Q4 2016, Long-Term Deferred Tax fell 4.49% year-over-year to -$5.7 million; the TTM figure through Dec 2016 stood at -$5.7 million (down 4.49% YoY), while the FY2016 annual figure was -$5.7 million, down 4.49% from the prior year.
- Long-Term Deferred Tax slipped to -$5.7 million in Q4 2016 per SLS's latest filing, from -$5.4 million in the prior quarter.
- Across five years, Long-Term Deferred Tax topped out at -$5.1 million in Q1 2012 and bottomed at -$5.7 million in Q4 2016.
- Historically, Long-Term Deferred Tax has averaged -$5.1 million across 5 years, with a median of -$5.1 million in 2012.
- Annual changes were most pronounced in 2012 — Long-Term Deferred Tax changed 0.0% — and 2015, when it dropped 7.22%.
- SELLAS Life Sciences' Long-Term Deferred Tax stood at -$5.1 million in 2012, then changed by 0.0% to -$5.1 million in 2013, then changed by 0.0% to -$5.1 million in 2014, then retreated by 7.22% to -$5.4 million in 2015, then dropped by 4.49% to -$5.7 million in 2016.
- Business Quant data shows SLS's Long-Term Deferred Tax at -$5.7 million in Q4 2016, -$5.4 million in Q4 2015, and -$5.1 million in Q3 2015.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | SELLAS Life Sciences | 2.32 Bn | 2.18 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2016 | -5.66 Mn |
| Dec 31, 2015 | -5.42 Mn |
| Sep 30, 2015 | -5.05 Mn |
| Jun 30, 2015 | -5.05 Mn |
| Mar 31, 2015 | -5.05 Mn |
| Dec 31, 2014 | -5.05 Mn |
| Sep 30, 2014 | -5.05 Mn |
| Jun 30, 2014 | -5.05 Mn |
| Mar 31, 2014 | -5.05 Mn |
| Dec 31, 2013 | -5.05 Mn |
| Sep 30, 2013 | -5.05 Mn |
| Jun 30, 2013 | -5.05 Mn |
| Mar 31, 2013 | -5.05 Mn |
| Dec 31, 2012 | -5.05 Mn |
| Sep 30, 2012 | -5.05 Mn |
| Mar 31, 2012 | -5.05 Mn |
| Dec 31, 2011 | -5.05 Mn |